Boston Scientific won the CE Mark of approval, allowing for the introduction of the Vercise Gevia Deep Brain Stimulation System in Europe. The Vercise Gevia is indicated for patients with movement disorders such as Parkinson’s, dystonia, and essential tremor, helping to calm down involuntary muscle activity that creates serious quality of life issues.
One of the main selling points of the system is the Vercise Neural Navigator 2 with STIMVIEW Technology, a software package that helps to program the implant by providing a visualization of how the stimulation will affect the brain. The size, shape, and direction of the stimulation can be tuned thanks to multiple independent current control (MICC) technology, which can result in optimal therapy while avoiding common side effects resulting from deep brain stimulation.
Additionally, the implant is MR conditional, keeping open the option for patients who wear it to receive MRI scans, as long as certain precautions are taken.
From the announcement:
“I now have the potential to better define the settings that can help patients because I have the ability to visualize their stimulation field while I am programming,” said Professor Patricia Limousin, M.D., Ph.D., neurologist, National Hospital for Neurology and Neurosurgery, Queens Square, London. “The Neural Navigator software brings together some of the most critical information I need to customize therapy for patients.”
“Five years ago, Boston Scientific was the first to bring an eight contact rechargeable platform offering 25 years of longevity, quickly followed by the introduction of the first directional lead powered by a small primary cell device,” said Maulik Nanavaty, senior vice president and president, Neuromodulation, Boston Scientific. “Today, we are thrilled to provide the first rechargeable, directional DBS system that is also Full Body MRI Conditional1 and the first programming software with STIMVIEW Technology. Boston Scientific is dedicated to providing transformative technology to equip clinicians and improve the lives of patients.”
Via: Boston Scientific…
